Analysts await Galectin Therapeutics Inc. (NASDAQ:GALT) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.22 EPS, down 22.73% or $0.05 from last year’s $-0.17 per share.

At the moment 3 analysts are watching Galectin Therapeutics Inc. (NASDAQ:GALT), 1 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 0.00 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 3 analysts have a mean target of 6.67 million.

In terms of earnings per share, 2 analysts have a -0.22 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.22 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -0.62 EPS.

The biggest institutional shareholders in Galectin Therapeutics Inc. include Empery Asset Management, LP which owns 1 million shares in the company valued at $2.01 million. Heights Capital Management Inc is the second biggest holder with 1 million shares currently valued at 1.94 million whilst Sabby Management LLC has 1 million shares valued at 1.78 million.

Total shares held by institutions as of the most recent company filings are 6,950,114 with a reported 297,468 bought and 769,622 sold. These holdings make up 29.03% of the company’s outstanding shares.

Currently insiders hold 5,451,017 shares in the business which makes up 22.78% of shares. The biggest holder currently is James C. Czirr who owns 883,630 shares (3.69% of those outstanding), whilst Dr. Theodore H. Zucconi,PhD holds 466,343 (1.95% of shares outstanding) and Rod D. Martin holds 202,089 (0.84% of shares outstanding).

The stock increased 0.66% or $0.01 during the last trading session, hitting $2.19. Galectin Therapeutics Inc. (NASDAQ:GALT) has risen 5.48% over the past 6 months and is uptrending.